Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Covington
Johnson and Johnson
Chinese Patent Office
Julphar
Colorcon
Baxter
US Department of Justice
Moodys
Medtronic

Generated: December 10, 2018

DrugPatentWatch Database Preview

XYREM Drug Profile

« Back to Dashboard

When do Xyrem patents expire, and when can generic versions of Xyrem launch?

Xyrem is a drug marketed by Jazz Pharms and is included in one NDA. There are eighteen patents protecting this drug and one Paragraph IV challenge.

This drug has thirty patent family members in seventeen countries.

The generic ingredient in XYREM is sodium oxybate. There are one thousand four hundred and fifty-four drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the sodium oxybate profile page.

Drug patent expirations by year for XYREM
Medical Subject Heading (MeSH) Categories for XYREM
Synonyms for XYREM
.Gamma.-Hydroxy butyrate
.gamma.-Hydroxy sodium butyrate
.gamma.-Hydroxybutyrate sodium
.gamma.-Hydroxybutyric acid decomposition product
.gamma.-Hydroxybutyric acid monosodium salt
.gamma.-Hydroxybutyric acid, sodium salt
.gamma.-OH
3-carboxypropoxy acid
30470-15-6
30IW36W5B2
4 HB
4-03-00-00774 (Beilstein Handbook Reference)
4-hydroxy-butanoic acid
4-hydroxy-butyric acid
4-Hydroxyacid
4-Hydroxyalkanoic acid
4-Hydroxybutanoic acid
4-Hydroxybutanoic acid #
4-Hydroxybuttersaeure
4-Hydroxybutyrate sodium
4-Hydroxybutyric acid
4-Hydroxybutyric acid monosodium salt
4-Hydroxybutyric acid sodium salt
4-Hydroxycarboxylic acid
4-OHB
52352-27-9
591-81-1
AA3E2AF0-AB7A-4A1E-A391-199C049D7162
AC1L1V58
AKOS022632618
Alcover
AN-8743
Anetamin
BDBM50023575
BRN 1720582
Butanoic acid, 4-hydroxy-
Butanoic acid, 4-hydroxy-, sodium salt
Butanoic acid,4-(1-oxobutoxy)-
Butyric acid, 4-hydroxy-
Butyric acid, 4-hydroxy-, monosodium salt
BUTYRIC ACID, 4-HYDROXY-, SODIUM SALT
C00989
C01991
C4H8O3
CHEBI:30830
CHEMBL1342
CTK4G5262
D0EP8X
DEA No. 2010
DTXSID2074740
EB 27
Gam-OH
Gamma Hydroxybutyric Acid
Gamma OH
gamma-hydroxy butyrate
gamma-Hydroxy sodium butyrate
gamma-Hydroxybutanoic acid
gamma-Hydroxybutyrate
gamma-Hydroxybutyrate sodium
gamma-Hydroxybutyric acid
gamma-Hydroxybutyric acid decomposition product
Gamma-Hydroxybutyric acid monosodium salt
Gamma-OH
GHB
GTPL4711
HSDB 6927
Hydroxyb
Hydroxybutyric acid monosodium salt
Hydroxybutyric acid-
HYDROXYBUTYRICACID
Juice
Liquid Ecstasy
LMFA01050006
LP090865
LS-46312
NCGC00247714-01
NSC84223
oxy-n-butyric acid
Oxybate
Oxybate sodium
PDSP1_000342
PDSP2_000340
SBI-0206686.P002
SCHEMBL10786
SHB
SJZRECIVHVDYJC-UHFFFAOYSA-N
Sodium .gamma.-hydroxybutyrate
Sodium .gamma.-oxybutyrate
Sodium gamma-oxybutyrate
Sodium Oxybate (4-hydroxybutanoic acid)
Somsanit
UNII-30IW36W5B2
utyric acid monosodium salt
WY 3478
WY-3478
Xyrem (TN)
ZINC1532805

US Patents and Regulatory Information for XYREM

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Jazz Pharms XYREM sodium oxybate SOLUTION;ORAL 021196-001 Jul 17, 2002 AA RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Jazz Pharms XYREM sodium oxybate SOLUTION;ORAL 021196-001 Jul 17, 2002 AA RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Jazz Pharms XYREM sodium oxybate SOLUTION;ORAL 021196-001 Jul 17, 2002 AA RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for XYREM
Drugname Dosage Strength RLD Date
➤ Subscribe Oral Solution 500 mg/mL ➤ Subscribe ➤ Sign Up

Supplementary Protection Certificates for XYREM

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00014 Denmark ➤ Sign Up PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REG. NO/DATE: EU/1/14/983 20150115
666 Luxembourg ➤ Sign Up PRODUCT NAME: DASABUVIR OU UN SEL QUI EN DERIVE, Y COMPRIS DASABUVIR SODIUMMONOHYDRATE. FIRST REGISTRATION: 20150119
C/GB98/040 United Kingdom ➤ Sign Up PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
AstraZeneca
US Army
Medtronic
Dow
Fuji
Moodys
Teva
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.